Increase in Abbreviated New Drug Applications (ANDA) over the past years has fostered the demand for API market. Furthermore, Indian companies making increased entries related to Drug Master File (DMF) indicates APIs market gaining traction. Stringent regulatory policies in the European Union is likely to restrain market growth. Patent expiry of biological drugs creates new growth opportunities for key API manufacturers.
The report segments the market on the basis of synthesis, type of manufacturer, type and therapy. Based on synthesis, this market is segmented into synthetic API and biotech API. The former is further segmented into Innovative synthetic APIS and generic synthetic APIS, while the latter is further segmented on the basis of products and type. The biotech APIS market, by product is further segmented into monoclonal antibodies, recombinant proteins and vaccines. On the basis of type of manufacturer, this market is segmented into captive API manufacturers, merchant API manufacturers, innovative APIS and generic APIS. On the basis of type, the market is segmented into innovative APIS segment and generic APIS segment. On the basis of therapy, the market is segmented into oncology, diabetes, cardiovascular disease, Cns and neurological disorders, orthopedic disorders, nephrology, ophthalmology, pulmonology, gastrointestinal disorders and endocrinology.
On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific, and Latin America, Middle East & Africa (LAMEA).
Key market players in this market are Teva Pharmaceutical Industries Limited, Dr. Reddys Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Novartis International AG, Albemarle Corporation, Sigma-Aldrich Corporation, Mylan Inc., and Allergan PLC
KEY BENEFITS FOR STAKEHOLDERS:
The report provides a comprehensive analysis of current & future market trends, key market challenges and emerging avenues for the growth of this market globally.
The report offers latest technological innovations and the recent R&D developments.
The report offers an insight into competitive landscape in terms of new technological developments, untapped segments, and value chain analysis.
This report entails the detailed quantitative analysis of the current market and estimations through 2014 and 2020, which assists in identifying the prevailing market opportunities.
The report offers detailed segmentation and analyzes the key segments in terms of market size by value and volume and country-level analysis to provide an in-depth understanding of the market.
Porters Five Forces analysis is offered in the report along with highlighting bargaining power of buyers and suppliers.
The report offers strategic analysis of financial status of key market players, and highlights market share of key vendors.
The report offers information on the status of new projects along with offering investment feasibility analysis of the same.
KEY SEGMENATATION
By Synthesis
Synthetic Active Pharmaceutical Ingredient
Innovative Synthetic APIS
Generic Synthetic APIS
By Product
Monoclonal Antibodies
Recombinant Proteins
Vaccines
By Type
Innovative Biotech APIS
Biogenerics/Biosimilars
By Type of Manufacturer
Captive API Manufacturers
Merchant API Manufacturers
Innovative APIS
Generic APIS
By Type
Innovative APIS Segment
Generic APIS Segment
By Therapy
Oncology
Diabetes
Cardiovascular Disease
Cns and Neurological Disorders
Orthopedic Disorders
Nephrology
Ophthalmology
Pulmonology
Gastrointestinal Disorders
Endocrinology
By Geography
North America
Europe
Asia-Pacific
LAMEA
Key Company Profile
Teva Pharmaceutical Industries Limited
Dr. Reddys Laboratories Ltd.
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Novartis International AG
Albemarle Corporation
Sigma-Aldrich Corporation
Mylan Inc.
Allergan PLC.
The report segments the market on the basis of synthesis, type of manufacturer, type and therapy. Based on synthesis, this market is segmented into synthetic API and biotech API. The former is further segmented into Innovative synthetic APIS and generic synthetic APIS, while the latter is further segmented on the basis of products and type. The biotech APIS market, by product is further segmented into monoclonal antibodies, recombinant proteins and vaccines. On the basis of type of manufacturer, this market is segmented into captive API manufacturers, merchant API manufacturers, innovative APIS and generic APIS. On the basis of type, the market is segmented into innovative APIS segment and generic APIS segment. On the basis of therapy, the market is segmented into oncology, diabetes, cardiovascular disease, Cns and neurological disorders, orthopedic disorders, nephrology, ophthalmology, pulmonology, gastrointestinal disorders and endocrinology.
On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific, and Latin America, Middle East & Africa (LAMEA).
Key market players in this market are Teva Pharmaceutical Industries Limited, Dr. Reddys Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Novartis International AG, Albemarle Corporation, Sigma-Aldrich Corporation, Mylan Inc., and Allergan PLC
KEY BENEFITS FOR STAKEHOLDERS:
The report provides a comprehensive analysis of current & future market trends, key market challenges and emerging avenues for the growth of this market globally.
The report offers latest technological innovations and the recent R&D developments.
The report offers an insight into competitive landscape in terms of new technological developments, untapped segments, and value chain analysis.
This report entails the detailed quantitative analysis of the current market and estimations through 2014 and 2020, which assists in identifying the prevailing market opportunities.
The report offers detailed segmentation and analyzes the key segments in terms of market size by value and volume and country-level analysis to provide an in-depth understanding of the market.
Porters Five Forces analysis is offered in the report along with highlighting bargaining power of buyers and suppliers.
The report offers strategic analysis of financial status of key market players, and highlights market share of key vendors.
The report offers information on the status of new projects along with offering investment feasibility analysis of the same.
KEY SEGMENATATION
By Synthesis
Synthetic Active Pharmaceutical Ingredient
Innovative Synthetic APIS
Generic Synthetic APIS
By Product
Monoclonal Antibodies
Recombinant Proteins
Vaccines
By Type
Innovative Biotech APIS
Biogenerics/Biosimilars
By Type of Manufacturer
Captive API Manufacturers
Merchant API Manufacturers
Innovative APIS
Generic APIS
By Type
Innovative APIS Segment
Generic APIS Segment
By Therapy
Oncology
Diabetes
Cardiovascular Disease
Cns and Neurological Disorders
Orthopedic Disorders
Nephrology
Ophthalmology
Pulmonology
Gastrointestinal Disorders
Endocrinology
By Geography
North America
Europe
Asia-Pacific
LAMEA
Key Company Profile
Teva Pharmaceutical Industries Limited
Dr. Reddys Laboratories Ltd.
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Novartis International AG
Albemarle Corporation
Sigma-Aldrich Corporation
Mylan Inc.
Allergan PLC.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
